About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 331 record(s)
Req # A-2022-001245
Adverse Drug Reactions (ADRs). Report numbers: E2B_05755714, E2B_05799009, E2B_05717142, E2B_05757499, E2B_05772388, 001009184, E2B_05784203, 001009876, E2B_05789901, E2B_05800104.Organization: Health Canada
April 2023
Req # A-2022-001268
Adverse Drug Reactions (ADRs). Report numbers: E2B_04875745, E2B_04113272, E2B_05577772, 000999862, 001001235, E2B_05539590, 001002862, E2B_05477751, 001002423, 001001169.Organization: Health Canada
April 2023
Req # A-2022-001300
Adverse Drug Reactions (ADRs) for ALENDRONIC ACID. Report numbers: 000720994, E2B 01745232, E2B 01792716, E2B 01907893, E2B 01907905, 000720957, E2B 01683502, E2B 01898113, E2B 01951232.Organization: Health Canada
April 2023
Req # A-2022-001313
Adverse Drug Reactions (ADRs) for ARIPIPRAZOLE. Report numbers: 001012259, E2B_05827743, E2B_05807662, E2B_05808475, E2B_05873004. ADRs for ABILIFY MAINTENA. Report numbers: E2B_05716578, E2B_05722001, E2B_05810459, E2B_05720638.Organization: Health Canada
April 2023
Req # A-2022-001314
Adverse Drug Reactions (ADRs). Report numbers: E2B_05801768, E2B_05801771, E2B_05801773, E2B_05801823, E2B_05801832, E2B_05801841, E2B_05801859, E2B_05801875, E2B_05801928, E2B_05801929.Organization: Health Canada
April 2023
Req # A-2022-001354
Adverse Drug Reaction (ADR) for DEXILANT. Report number: E2B_05885170. ADRs for ENTYVIO. Report numbers: E2B_05957614, E2B_05947821, E2B_05932175, E2B_05955071, E2B_05935607, E2B_05932203, E2B_05951484. ADR for VEDOLIZUMAB. Report number: 001019420. ADR for Ondansetron. Report number: E2B_05923043.Organization: Health Canada
April 2023
Req # A-2022-001391
Adverse Drug Reaction (ADR). Report number: E2B_05743467.Organization: Health Canada
April 2023
Req # A-2022-001392
Adverse Drug Reactions (ADRs). Report numbers: E2B_05884704, E2B_05941914.Organization: Health Canada
April 2023
Req # A-2022-001394
Adverse Drug Reactions (ADRs). Report numbers: E2B_05832355, E2B_05830513, E2B_05844317, E2B_05867002, E2B_05865692, 001014289, 001013455, E2B_05844058, E2B_05849075, E2B_05807659.Organization: Health Canada
April 2023
Req # A-2022-001395
Adverse Drug Reactions (ADRs). Report numbers: E2B_05864946, 001013739, E2B_05843069, 001015184, E2B_05843020, E2B_05811402, E2B_05841257, E2B_05872205, E2B_05810554, E2B_05815237.Organization: Health Canada
April 2023